Brook Byers has been a venture capital investor since 1972 and in 1984 he formed the first life science practice group in the venture capital profession to help Kleiner Perkins Caufield & Byers (KPCB) become a premier venture firm in the medical, health care and biotechnology fields. KPCB has invested in and helped build over 110 life sciences companies which have already developed hundreds of products to treat major underserved medical needs for millions of patients. Brook is currently a board member of nine companies including XDx (Chairman). He was formerly a director of IDEC Pharmaceuticals (chairman), Athena Neurosciences (chairman), Signal Pharmaceuticals, Arris Pharmaceuticals, Pharmacopeia, Ligand Pharmaceuticals (chairman), Insite Vision, Hybritech (chairman), Genprobe, Nanogen, and others. Brook was president and a director of the Western Association of Venture Capitalists and is a contributing author to the book “Guide to Venture Capital”. Raised in Atlanta, Georgia, Brook graduated in electrical engineering from Georgia Tech and received an M.B.A. from Stanford Graduate School of Business. He serves the community as a trustee of various schools, museums and foundations including UCSF Medical Center, the California Healthcare Institute and the New Schools Foundation.

Pierre Cassigneul is the president and chief executive officer of XDx Inc. Mr. Cassigneul has more than 25 years of senior management experience in the healthcare and medical device industries, both in Europe and the United States, including the global launch of several successful high-tech products. He joined XDx from the consulting firm, Stone Bridge Management LLC, where he was an operating partner. Formerly, as the vice president of diabetes management at Becton Dickinson & Co, he oversaw completion of the product, clinical trials and regulatory submissions. Mr. Cassigneul has held top management positions at Bayer in the diabetes self-testing business unit, where he developed and launched a new patient-monitoring system; Ortho Diagnostic Systems (J&J) in the AIDS and hepatitis business unit, where he launched a complete line of blood screening products; and Abbott Laboratories in the diagnostic division, where he launched the first HIV test for screening the European blood supply. He serves on the board of The Personalized Medicine Coalition. Mr. Cassigneul holds a management degree from the Ecole Superieure de Commerce de Reims, France.

Fred is a managing director at TPG (Texas Pacific Group) Ventures. He also retains a position as a professor of cellular and molecular pharmacology at the University of California, San Francisco. Fred also serves as a member of the boards of GenomicHealth, XDx, Kemia, Five Prime Therapeutics and Matrix Pharmaceuticals. He is also a member of the investment committee of the board of Quintiles Transnational. He received his M.D. from Stanford in 1984, his D.Phil. from Oxford as a Rhodes Scholar in 1980 and his B.S. in 1978 from Yale University. Fred has been a member of the faculty of UCSF since 1986 and is best known for his work on protein structure and the conformational basis of prion disease.

Vijay Lathi is a managing director of New Leaf Venture Partners, a healthcare focused venture capital firm formed by the healthcare team formerly at Sprout Group. He currently sits on the board of directors of Aviir, Relypsa, Kalypsys, Neurovista, Proteogenix, and XDx. Vijay joined Sprout in 1998 after working as an analyst in the Healthcare Venture Capital Group at Robertson Stephens & Co. and Cornerstone Research. Vijay graduated from the Massachusetts Institute of Technology and Stanford University where he received his B.S. and M.S. in chemical engineering, with an emphasis on the application of engineering to life science technology. Vijay is also a member of AIChE.

G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves as chairman of the board of Pharmasset, and is a member of the boards of directors of Catalyst Biosciences, DepoMed (Amex: DMI), Targacept (NASDAQ: TRGT), Proventys and Phytomedics. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide. In 2002, Mr. Burrill was recognized as the biotech investment visionary by the prestigious Scientific American magazine (The Scientific American 50). Mr. Burrill is a founder of the Foundation for the National Medals of Science and Technology and currently serves on its board of directors. Some of his not for profit activities include serving on the board of directors for the Bay Area Science Infrastructure Consortium, BayBio, the California Healthcare Institute, the Exploratorium, The Kellogg Center for Biotechnology, Research America, Campaign for Medical Research, The National Health Museum, and the University of California, San Francisco (UCSF) Foundation. He is also the chairman of the Mayor’s Biotech Advisory Committee (MAYBAC).

David is the founder, President, and CEO of CardioDx . Prior to founding CardioDx, David was a venture partner at TPG Ventures, where he was the interim CEO of XDx. Previously, he was the founder, president and CEO of iScribe (which was sold to AdvancePCS-now Caremark in December, 2001). Prior to iScribe, David was president of Oncology Therapeutics Network (sold to Bristol-Myers Squibb in 1996). David also served as CFO of OTN's parent company, Axion, from 1990 to 1993. Prior to Axion, he was with Cole Gilburne Fund, an early stage, technology focused venture capital firm. David received his MBA from Stanford University and B.S. from Williams College.

Dr. Ralph Snyderman is chancellor emeritus and James B. Duke Professor of Medicine at Duke University. Prior to that, he served as chancellor for health affairs, executive dean of the School of Medicine, and president and chief executive officer of the Duke University Health System, one of the few fully integrated health systems in the country. Dr. Snyderman led the transition of this excellent medical center into an internationally recognized model for academic medicine. During his tenure, the medical school and hospital ranked amongst the nation's best. Dr. Snyderman was senior vice president for medical research and development at Genentech, Inc. Dr. Snyderman received his M.D., magna cum laude, in 1965 from the Downstate Medical Center of the State University of New York and he served his internship and residency in medicine at Duke. Pre-eminent in his field of immunology, Dr. Snyderman is internationally recognized for his research contributions to our understanding of inflammation that have led to numerous important discoveries published in nearly 350 manuscripts over the last 25 years. Additionally, Dr. Snyderman serves as a member of the board of directors of Procter and Gamble Inc. as well as several other boards.

Peter is President and CEO of BioCardia, Inc., a developer of investigational cardiovascular biotherapeutic delivery systems and FDA cleared interventional catheter systems . These systems currently enable investigational clinical studies of cell and gene transplantation therapies to treat myocardial infarction, heart failure, and ischemia. Peter was the founding president and CEO for XDx. He also participates as a director and acting CEO at Lumen Therapeutics. Previously, Peter was with Ventritex (acquired by St Jude Medical and became their Cardiac Rhythm Management division). Peter received his Ph.D. in bioengineering/pharmaceutical chemistry from the University of California San Francisco and University of California Berkeley, his Management of Technology certificate from the Haas School of Business, University of California Berkeley, and both his master of science and bachelors of science degrees in mechanical engineering from the Columbia University School of Engineering and Applied Sciences.